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Abstract 
Background: Venous thromboembolism (VTE) is relatively common in children with 
acute lymphoblastic leukemia (ALL). Thrombotic risk factors in ALL are asparaginase 
and steroids. However, within the ALL populations treated on the same regimen, it is 
less clear which other risk factors play a role. Furthermore, few data are available on 
the effect of VTE on ALL outcomes.
Methods: In 778 children (1- 18 years) with newly diagnosed precursor- B- lineage or 
T- lineage ALL, treated in the Dutch Childhood Oncology Group (DCOG) ALL- 10 pro-
tocol in the Netherlands (October 2004 to April 2013), we conducted a nested case 
control study with 59 VTE cases and 118 controls to identify risk factors for VTE.
Results: Fifty- nine of 778 ALL patients developed VTE (7.6%), with cerebral venous 
sinus thrombosis (CVST) in 26 of 59 patients (44.1%). VTE occurred during induction 
treatment in 59.3% (n = 35) and in 40.7% (n = 24) during medium risk intensification. 
Conditional multivariable logistic regression analysis showed that age and ALL sub-
type were significantly associated with VTE (age ≥7 years: OR 2.72, 95% CI 1.33- 
5.57; ALL subtype T- ALL: OR 2.95, 95% CI 1.02- 8.57). A multivariable Cox model 
showed no association between the occurrence of VTE and event free survival. In 
CVST patients, permanent disability was present in 34.6%.
Conclusion: Within this large pediatric ALL cohort, we demonstrated a high morbid-
ity in CVST patients. Age ≥7 years at diagnosis and T- ALL subtype were the main risk 
factors for VTE, and should be considered in preventive strategies.
K E Y W O R D S
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1  | INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common form 
of cancer in children.1 Over the past decades, survival rates in-
creased tremendously to a 5- year overall survival of >90%2,3 due 
to more insight in the pathogenesis of ALL and optimized treat-
ment strategies.4 The potential drawback of these treatment reg-
imens is the burden of toxic effects. A severe and well- described 
complication in ALL patients is venous thromboembolism (VTE).5 
Reported incidences of VTE in childhood ALL varies from 1.1% 
to 36.7%.6,7
The overall mortality rate in ALL patients as a result of VTE 
varies between 0% and 4.8%.6 A substantial proportion of VTE 
in ALL is due to cerebral venous sinus thrombosis (CVST) with a 
reported mortality between 0% and 28%.8-11 Morbidity includes 
recurrent thrombosis, neurologic changes, catheter removal, 
bleeding due to antithrombotic agents, and the development of 
the postthrombotic syndrome.12-14,15 Furthermore, VTE can lead 
to suboptimal ALL therapy, due to the necessity to interrupt, delay, 
or even discontinue chemotherapy, and thereby to inferior disease 
outcomes.16
Mechanisms underlying the increased VTE risk in ALL are not 
completely understood. Previous studies have shown that the disease 
itself, as well as treatment components, and patient characteristics, 
such as age, and thrombophilia, may contribute to a prothrombotic 
state.6,8,12-14,17,18 The highest VTE risk arises in the first weeks of ALL 
treatment, especially during the use of asparaginase, in combination 
with corticosteroids.13,17,19 Asparaginase is one of the most import-
ant risk factors for VTE, as it can induce coagulation disorders by 
decreasing natural anticoagulant proteins such as antithrombin (AT), 
protein C and protein S. However, it is also an essential component in 
modern ALL treatment, as insufficient exposure to asparaginase was 
shown to lead to decreased survival.3,16,20 A better understanding of 
specific clinical risk factors for VTE during asparaginase treatment in 
ALL patients will be helpful to identify patients, in whom preventive 
measures might be beneficial, thereby improving the quality of ALL 
treatment.
The aim of this study is to assess the risk of symptomatic VTE 
during ALL treatment and identify clinical risk factors for VTE during 
asparaginase treatment in a large, well- defined large cohort of chil-
dren with ALL treated in the Dutch Childhood Oncology Group 
(DCOG) ALL- 10 study, using a case- control design. In addition, we 
explored the effect of the development of VTE on the event free 
survival (EFS).
2  | METHODS
2.1 | Study population
We retrospectively analyzed children with ALL treated in the DCOG 
ALL- 10 protocol.21 Briefly, the study included 778 children with newly 
diagnosed ALL (precursor- B lineage and T- lineage ALL) between the 
ages of 1 and 18 years between October 2004 and April 2013 in six 
Dutch pediatric cancer centers. For each VTE case, we randomly se-
lected two control patients without VTE from the ALL- 10 cohort (1:2 
ratio). Controls were matched by treatment center only. The study 
was performed in accordance with the Declaration of Helsinki, and 
the institutional medical ethics committee approved this study.
2.2 | Treatment
All children received the same induction chemotherapy containing 
prednisone 60 mg/m2/day (days 1- 28), and eight doses of native 
E.coli asparaginase (5000 IU/m2 per dose) every 3 days (Figure 1). 
Patients were stratified into three risk groups after induction treat-
ment: standard risk, medium risk, and high risk. Medium risk patients 
received intensification therapy containing dexamethasone (6 mg/
m2/day, 5 days every 3 weeks) and PEG- asparaginase (2500 IU/m2, 
15 doses in 30 weeks).
In all patients, a CVC was placed upon treatment initiation. None 
of the patients received low- molecular- weight heparin (LMWH) or AT 
supplementation routinely as thrombosis prophylaxis during ALL treat-
ment. Children received fresh frozen plasma (FFP) if there was a bleed-
ing tendency and fibrinogen levels dropped below 0.6 g/L on discretion 
of the treating physician, and platelet transfusions during induction 
phase, if platelet levels dropped below 10 × 109/L. Patients also re-
ceived small amounts of unfractionated heparin (3 mL of 100 IU/mL) 
for prophylaxis of CVC blockage according to local standard of care.
2.3 | Outcome definitions and data collection
VTE events were prospectively recorded centrally in the DCOG 
ALL- 10 study on toxicity reports. Patients with symptomatic VTE 
were identified from these reports (grade 3, 4, and 5 only, based on 
Common Terminology Criteria for Adverse Events (CTCAE), version 
3.0; 2006). Screening for asymptomatic VTE was not performed. 
We did not include patients with incidentally found asymptomatic 
VTE, to avoid introduction of bias as result of missed asympto-
matic thrombi. Detailed patient and treatment information was 
Essentials
• Venous thromboembolism (VTE) is a common complication in pediatric acute lymphoblastic leukemia (ALL).
• This Dutch study identified incidence and risk factors for VTE.
• 7.6% of patients developed VTE, of which 44.1% were cerebral venous sinus thrombosis (CVST). Age and ALL subtype were risk factors for 
VTE.
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systematically obtained from patient records using standardized 
data collection forms for all patients with VTE.
VTE was defined as symptomatic venous thrombosis or pul-
monary embolism (PE), including CVC- associated VTE requiring 
intervention, objectively confirmed by appropriate imaging tests 
(computerized tomography [CT] or magnetic resonance imaging 
[MRI] for CVST, compression [Doppler] ultrasonography or venog-
raphy for DVT of the leg or upper extremity vein thrombosis [UEVT] 
and CVC- VTE, and [spiral] CT for pulmonary embolism).
VTE was considered CVC- associated when it was located in the 
same vein as the catheter.
Central nervous system (CNS) involvement of ALL was defined 
as >5 leukocytes/μL cerebrospinal fluid (CSF) with identifiable leu-
kemic cells, or intracerebral or meningeal mass seen on MRI or CT 
scans, or cranial nerve palsy (irrespective of CSF or imaging findings), 
or retinal involvement (irrespective of CSF findings). Sepsis was de-
fined according to the Laboratory- confirmed bloodstream infection 
(LCBI) criteria 1 and 2 of the Centers for Disease Control (CDC) and 
Prevention.22
Part of the children with VTE were tested for congenital throm-
bophilia, eg, Factor V Leiden or prothrombin G20210A mutation, or 
a reduced AT, protein C or S level according to local protocol.
2.4 | Statistical analysis
VTE was expressed as percentage. Differences between children 
with and without VTE were calculated using Mann- Whitney U, 
Chi2- , or Fisher's exact tests. We used a case- control design to iden-
tify potential clinical risk factors for VTE. Potential risk factors for 
VTE evaluated were age, sex, ALL subtype (B- ALL or T- ALL), ALL 
risk group (medium risk vs standard risk or high risk), presence of 
thrombophilia, CNS involvement in ALL and baseline absolute num-
ber of blasts in peripheral blood. Age and baseline absolute number 
of blasts in peripheral blood were explored as dichotomous vari-
ables, using the median value of all cases and controls (7 years and 
42.5 × 109/L, respectively). The cumulative VTE- free survival after 
ALL diagnosis was estimated with Kaplan Meier methodology. To 
study the association between risk factors and VTE univariable and 
F IGURE  1 Treatment protocol of the Dutch Childhood Oncology Group (DCOG) ALL- 10 study
INCLUSION
INDUCTION
MAINTENANCE
PROT
IA + IB
PROT M
(starts 2 wks
after
completion
of PROT IB)
Prednisone 60 mg/m2/d i.v. or p.o. (d 1-28)
Vincristine 1.5 mg/m2/d i.v. (d 8,15,22,29)
Daunorubicin 30 mg/m2/d i.v. (d 8,15,22,29)
MTX i.t. dose acc. to age (d 1)
ARA-C 75 mg/m2/d i.v. (4 blocks of 4 days)
MTX/ARA-C/DAF i.t. dose acc. to age (4x for 
prophylaxis,>4x in case of CNS
localization of ALL)
L-Asparaginase 5000 IU/m2/d i.v. (d 12,15,18,21,
24,27,30,33)
MEDIUM RISK (MR) PROTOCOL; based on HIGH RISK (HR) PROTOCOL; based on
HR COURSE 1-6 (allogenic SCT after HR course 3
if eligible for SCT and donor available)
PROT IV + MAINTENANCE
MR INTENSIFICATION/CONTINUATION
(104 WEEKS)  
STANDARD RISK (SR) PROTOCOL;
Cyclophosphamide 1000 mg/m2/d i.v. (d 36,64)
6-Mercaptopurine 25 mg/m2/d p.o. (days 1-56)
6-Mercaptopurine 60 mg/m2/d p.o. (days 36-63)
High-dose MTX 5000 mg/m2/d i.v (d 8,22,36,50)
Leukovorin 15 mg/m2/d i.v. (following high-dose MTX)
MTX/ARA-C/DAF i.t. dose acc. to age (d 8,22,36,50)
based on
- no HR criterium
- no HR criterium
- prednisone poor response on d 8
- no CR at d 33
- no SR criterium
- MRD at time point 1+2 negative
- Dexamethasone 10 mg/m2/d p.o.
(d 1-15)
- PEG-Asparaginase         
       2500 IU/m2/d i.v. (d 1)
- Dexamethasone 6 mg/m2/d p.o.
   (for 5 days, every 3 weeks)
- PEG-Asparaginase 2500 IU/m2/d i.v.
        (every 2 weeks x 15; week 1, 3, 5, 7, 9,
11, 13, 15, 17, 19, 21, 23, 25, 27, 29)
p.o. = oral; i.v. = intravenous; i.t. = intrathecal; ALL = acute lymphoblastic leukemia; ARA-C = cytosine arabinoside; CNS = central nervous 
system; CR = complete remission; DAF = diadreson F aquosum; MRD = minimal residual disease; MTX = methotrexate; 
SCT = stem cell transplantation.  
- t(4;11) or t(9;22) presence
- MRD ≥ 10–3 at d 33 and at d 79
(before start of PROT M)
- L-Asparaginase 10 000 IU/m2/d i.v.
              (d 22, 25, 29, 32) in HR course 1, 2, 4, 5
Full treatment schedules are included for the induction cycles Protocol IA + IB and M. For the SR, MR and HR protocol, 
only the use of steroids and asparaginase are listed, while other treatment agents are not 
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multivariable conditional logistic regression models were estimated 
to take into account the case- control design models.23 Results are 
expressed as odds ratio (OR) with corresponding 95% confidence 
intervals (CI).
The effect of VTE on EFS (defined as non- response, relapse, sec-
ondary malignancy, or death), was investigated by using an multi-
variable Cox regression analysis, with risk factors for VTE as age, 
ALL subtype, risk group. Results are presented as hazard ratio (HR) 
with corresponding 95% CIs. A two- sided P < 0.05 was considered 
statistically significant. IBM SPSS Statistics 22.0 for Windows (IBM, 
IBM, Armonk, NY) was used for descriptive and estimation of time 
to VTE and Cox proportional hazard model. Analysis concerning the 
conditional logistic regression models is performed in R- software 
environment.
3  | RESULTS
3.1 | Patients and VTE events
VTE events occurred in 59 of 778 included children (7.6%) during 
treatment in the ALL- 10 study. Of 59 children with VTE, 26 (44.1%) 
experienced CVST, 12 patients (20.3%) DVT of the leg, three pa-
tients (5.1%) PE, and 18 patients (30.5%) ULVT or CVC- related 
thrombosis. None of these patients had previously experienced VTE 
(Table 1). Forty of 59 children were tested for congenital thrombo-
philia; in only two children, thrombophilia was found (one heterozy-
gous prothrombin G20210A mutation, one heterozygous Factor V 
Leiden mutation).
3.2 | VTE events and ALL treatment
VTE events occurred during induction treatment of the DCOG ALL- 
10 treatment protocol in 35 patients (59.3%), and during medium risk 
intensification treatment in 24 patients (40.7%). Patients stratified 
as standard risk or high risk (n = 16) did not experience any episode 
of VTE beyond induction treatment. The cumulative VTE- free sur-
vival after ALL diagnosis was 95.5%, 92.7% and 92.4% after 9, 55, 
and 120 weeks, respectively (Figure 2).
Fifty- three of 59 patients (89.8%) with VTE had received aspara-
ginase therapy <21 days prior to VTE occurrence. Thirty- eight of 59 
patients (64%) received corticosteroids <5 days before development 
of VTE. All these patients had concomitant use of asparaginase. 
CVST, occurred shortly after asparaginase administration (median 
time 3 days; range 1- 60), compared with other types of VTE (median 
time 7.5 days; range 2- 177). Twenty- two of 26 (87.5%) CVST patients 
received simultaneous administration of corticosteroids, compared 
to 17/33 (51.5%) in other VTE patients (P = 0.008).
3.3 | Identification of clinical risk factors for VTE 
in the case control study
Baseline characteristics for cases and controls are shown in Table 1. 
Univariate conditional logistic regression analysis showed that age 
as a dichotomous variable (age ≥7) ALL subtype (T- ALL) and ALL me-
dium risk group were statistically significantly associated with VTE 
(Table 2). In a multivariable conditional logistic regression analysis age 
and ALL subtype remained statistically significantly associated with 
VTE. Of all VTE, 24.1% occurred in patients aged 1- 5 years, 48.3% 
in patients aged 6- 12 years and 27.6% in patients aged ≥13 years.In 
a univariate conditional logistic regression subanalysis for CVST, in-
cluding age, ALL subtype, and ALL risk group, age ≥7 years and ALL 
medium risk group were the only significantly associated risk factor 
for CVST (Table 3). In a conditional multivariable logistic regression 
analysis none of these factors remained statistically significantly as-
sociated with CVST. Age distribution in patients with CVST was 16%, 
56%, and 28% in age groups 1- 5, 6- 12, and ≥13 years, respectively.
TABLE  1 Patient characteristics
Cases with VTE 
(N = 59)
Controls without 
VTE (N = 118)
Male, n (%) 35 (59.3) 76 (64.4)
Median age at inclusion, 
y (IQR)
11 (6.0- 14.0) 5 (2.0- 9.0)
ALL subtype
B- ALL, n (%) 43 (72.9) 100 (84.7)
T- ALL, n (%) 16 (27.1) 12 (10.2)
Unknown, n (%) — 6 (5.1)
Risk groupa
Standard risk, n (%) 5 (8.5) 27 (22.9)
Medium risk, n (%) 43 (72.9) 64 (54.2)
High risk, n (%) 7 (11.9) 4 (3.4)
Unknown/other, n (%) 4 (6.8) 23 (19.5)
Thrombophilic 
mutationsb, n (%)
2 (3.4) 1 (0.8)
CNS involvement of 
ALLc, n (%)
4 (6.8) 3 (2.5)
Median baseline 
leukocyte count (IQR)
9.3 (5.1- 50.1) 9.4 (3.9- 33.0)
Median baseline platelet 
count (IQR)
66 (34.0- 136.0) 60 (28.0- 119.0)
Median baseline absolute number of blasts (IQR)
In peripheral blood 47 (10.3- 76.8) 39.5 (12.3- 78.0)
In bone marrow 87 (80.0- 94.0) 89 (80.0- 94.0)
Sepsis, n (%) 6 (10.2) 13 (11.0)
Mortality, n (%) 8 (13.6) 13 (11.0)
Extramedullary disease, 
n (%)
7 (11.9) 11 (9.3)
ALL, acute lymphoblastic leukemia; CNS, central nervous system; IQR, 
interquartile range; NS, not significant; VTE, venous thromboembolism.
aRisk group is based on response to chemotherapy, initial CNS and testis 
involvement, presence of specific chromosomal abnormalities in the leu-
kemic cells (see Methods). 
bPercent of tested patients; defined as presence of the Factor V Leiden 
or prothrombin G20210A mutation. 
cExtramedullary disease was defined as presence of a mediastinal mass, 
testicular involvement, or CNS involvement. 
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3.4 | Treatment and outcome of VTE
Median follow- up of the 59 VTE patients was 4.9 years (range 0.7- 
9.6 years). Fifty- three patients were treated with LMWH. Three pa-
tients with CVST did not receive LMWH due to concurrent bleeding. 
In one child with CVC related VTE the CVC was removed without 
anticoagulant treatment, and one patient had successful local low- 
dose thrombolytic therapy. In one patient, the reason for withhold-
ing anticoagulant treatment was unknown. None of these patients 
experienced progression of their clot.
Median duration of LMWH treatment was 17 weeks (range 2- 
103). One patient with cerebral aspergillosis experienced an intrace-
rebral bleeding 2 days after the start of anticoagulant therapy. Five 
patients (8.5%) had a recurrent VTE. Four out of five patients used 
LMWH while developing recurrent VTE, three therapeutic and one 
prophylactic dosages. In the fifth patient, information on the use of 
LMWH was not known. Two of the patients with therapeutic LWMH 
had an invasive aspergillosis infection at the time of recurrent VTE. 
The patient with prophylactic LMWH died due to recurrent VTE (PE).
In 25 of 59 patients (42.4%), VTE occurrence led to ALL treat-
ment protocol changes, such as delay or premature cessation of 
asparaginase therapy (n = 10), intrathecal therapy (n = 1), or both 
asparaginase and intrathecal therapy (n = 12). Details of withheld 
therapy doses were not retrieved. In one patient, only dexametha-
sone was cancelled, and in one patient treatment adjustments were 
unknown.
Eight of 59 patients (13.6%) with VTE died, but none directly 
due to the initial thrombotic event, compared to 13 of 118 control 
patients (11%). In the CVST subgroup, no patients died directly 
due to their thrombosis. Overall, four of 26 patients (15.4%) with 
CVST died, compared to three of 52 control CVST patients (5.8%).
In patients with CVST, acquired permanent disability as a result 
of the CVST was present in nine patients (34.6%). Most common 
was symptomatic epilepsy. Two patients had symptomatic epi-
lepsy, focal motor deficits and cognitive disabilities. One patient 
had focal motor deficits. Six patients (30.8%) had symptomatic 
epilepsy and were treated with anti- epileptic treatment for more 
than 1 year.
3.5 | VTE and outcome of ALL
Multivariable Cox model showed no association between the occur-
rence of all types of VTE and event free survival (HR = 1.4, 95% CI 
0.69- 2.72.
4  | DISCUSSION
This study demonstrated that VTE occurred in 7.6% of children dur-
ing ALL treatment. Multivariable analyses using a case- control design 
F IGURE  2 Cumulative thrombosis- free survival after diagnosis 
of acute lymphoblastic leukemia
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TABLE  2 Risk factors for VTE
Variable
Univariate OR 
(95% CI)
Multivariable 
OR (95% CI)
Age dichotomous (≥7 vs <7 y) 3.41 (1.72- 6.75) 2.72 (1.33- 5.57)
Male versus female 0.86 (0.64- 2.12)
T- ALL versus B- ALL 3.75 (1.40- 10.04) 2.95 (1.02- 8.57)
MR group versus SR, HR, 
or unknown
2.40 (1.17- 4.89) 1.82 (0.85- 3.92)
High baseline absolute 
number of blasts in PB 
(≥42.5 vs <42.5)
1.39 (0.71- 2.73)
CNS involvement of ALL 2.83(0.63- 12.69)
ALL, acute lymphoblastic leukemia; BM, bone marrow; CI, confidence 
interval; CNS, central nervous system; HR, high risk; MR, medium risk; 
OR, odds ratio; PB, peripheral blood; SR, standard risk; VTE, venous 
thromboembolism.
Extramedullary disease was defined as presence of a mediastinal mass, 
testicular involvement, or CNS involvement.
TABLE  3 Risk factors for CVST
Variable
Univariate OR 
(95% CI)
Multivariable OR 
(95% CI)
Age dichotomous  
(≥7 vs <7 y)
3.12 (1.07- 9.10) 2.31
Male versus female 1.06 (0.41- 2.71)
T- ALL versus B- ALL 1.80 (0.43- 7.46) 1.60 (0.44- 7.30)
MR group versus SR, 
HR, or unknown
4.14 (1.10- 15.61) 2.64 (0.66- 10.55)
High baseline absolute 
number of blasts in PB 
(≥42.5 vs <42.5)
1.05 (0.04- 3.04)
ALL, acute lymphoblastic leukemia; BM, bone marrow; CI, confidence 
interval; CVST, cerebral venous sinus thrombosis; HR, high risk; MR, me-
dium risk; PB, peripheral blood; SR, standard risk; OR, odds ratio.
Extramedullary disease was defined as presence of a mediastinal mass, 
testicular involvement, or CNS involvement.
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showed that age ≥7 years was a main risk factor for VTE, thus con-
firming other studies.24,25 Accordingly, it is recommended to include 
age in preventive strategies for VTE during ALL treatment. An analy-
sis of the developmental hemostatic system showed a relative pro-
tective effect against VTE in young infants, compared with adults, 
with decreased levels of several critical procoagulant factors and in-
creased levels of certain natural anticoagulants.26 As the hemostatic 
system matures with increasing age in children, this may also increase 
their baseline VTE risk towards the level of young adults. Older chil-
dren may, therefore, represent a subgroup of pediatric ALL patients 
in whom thromboprophylaxis with LMWH might be beneficial, and 
safe.27,28 FFP or antithrombin supplementation have been described, 
but results on efficacy are inconsistent and inconclusive.29-34
In the univariate conditional logistic regression model, T- ALL 
subtype (OR 3.75; 95% CI 1.40- 10.04) and ALL medium risk group 
(OR 2.40; 95% CI 1.17- 4.89) were also significantly associated with 
VTE in addition to age. In the multivariable analysis T- ALL sub-
type appeared to be an independent risk factor, as in the study of 
Giordano. That study described higher thrombin levels in T- ALL pa-
tients.35 ALL medium risk group was no longer significantly associ-
ated with VTE.
In concordance with other studies, asparaginase therapy is an 
important risk factor for VTE, during ALL treatment.7,15,18 In our 
study, a majority of patients received asparaginase prior to VTE. 
Although the standard and high risk protocols both include one or 
more singular doses of asparaginase, it is likely that the repetitive 
and long- term use of asparaginase in the induction cycles and me-
dium risk protocol particularly predispose to a high VTE risk. This is 
in line with previous studies that demonstrated that length of ex-
posure to, but not the dosages of asparaginase correlates with VTE 
risk.7,8 In addition, a previous study showed no correlation between 
the level of asparaginase activity and the occurrence of VTE.36
We also observed that CVST occurred very shortly after adminis-
tration of asparaginase therapy in comparison with other types of VTE. 
This might be an explanation for the observation that CVST events 
occurred significantly earlier during treatment compared with other 
types of VTE. It is possible that patients with CVST represent a sub-
group of patients at highest risk of VTE. However, specific risk factors 
and mechanisms explaining the predisposition for CVST during ALL 
treatment are still unclear.10,37 One risk factor might be the simulta-
neous administration of steroids as combination therapy (asparaginase 
and steroids) occurred twice as much in patients with CSVT than in 
patients with other VTE.11
In over one- third (40%) of the VTE patients, VTE led to dose ad-
justments or interruption of asparaginase therapy. Asparaginase is a 
central component of ALL treatment, and not completing the full total 
dosage, could lead to a significantly worse outcome.16 In our study, no 
statistical significance association was found between occurrence of 
VTE and EFS. It is ambiguous if reintroduction of asparaginase after 
VTE is safe. Two studies described reintroduction of asparaginase, in 
which most patients received LMWH prophylaxis and no recurrent 
thrombosis occurred.38,39 However, another study described a high 
VTE recurrence rate, despite anticoagulant therapy.18 Therefore, the 
efficacy and safety of thromboprophylaxis during ALL treatment re-
main unclear, and future studies are required for further assessment. 
In the meantime, identifying risk factors and those patients at highest 
risk may help to prepare such studies.
Although VTE events were collected prospectively, complete 
data retrieval was not possible for some variables, such as withheld 
therapy after VTE diagnosis. Although treatment protocols were 
standardized in the involved treatment centers, differences in care 
and awareness may have influenced VTE incidence. Moreover, we 
used a case- control design instead of the entire ALL- 10 cohort for 
our analysis; despite using a 1:2 ratio for cases and controls, this may 
have affected the power of our results. In addition, we did not sys-
temically study the presence of congenital thrombophilia in the ALL 
patients.
In conclusion, age ≥7 years at diagnosis and T- ALL subtype are 
the main risk factors for VTE in children with ALL treated within a 
well- defined setting including steroids and asparaginase. This under-
lines the importance of preventive strategies in those children with 
ALL at high- risk for VTE.
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